Related Experiment Video

Updated: May 2, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

232

Development of ventricular assist devices in China: present status, opportunities and challenges

Kaiyun Gu1, Yu Chang2, Bin Gao1

  • 1School of Life Science and BioEngineering, Beijing University of Technology, Beijing, China.

European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|February 27, 2014
PubMed

Insights

China faces a critical need for mechanical circulatory support due to rising heart failure cases. Ventricular assist device (VAD) development has been slow, with no approved systems for clinical use despite decades of research.

Area of Science:

  • Cardiovascular Engineering
  • Biomedical Devices
  • Medical Technology in China

Background:

  • Increasing prevalence of heart failure and limited organ donors necessitate advanced treatments.
  • Mechanical circulatory support systems, such as ventricular assist devices (VADs), are crucial for managing end-stage heart disease.
  • China has a significant and growing demand for effective VADs.

Purpose of the Study:

  • To provide an overview of the current state of VAD research and development in China.
  • To analyze the reasons behind the slow progress of VAD clinical application in China.
  • To discuss the challenges hindering the clinical development of mechanical circulatory support in China.

Main Methods:

  • Review of experimental and clinical research programs on blood pumps and VADs in China over the past three decades.
  • Analysis of factors contributing to the slow development and lack of clinical approval for VADs.
  • Discussion of the obstacles to widespread clinical adoption of VADs.

Main Results:

  • Despite extensive research over 30 years, VAD development in China has lagged significantly compared to international standards.
  • No VAD system has yet received regulatory approval for clinical application in China.
  • Multiple factors contribute to the slow progress, including research, development, and regulatory hurdles.

Conclusions:

  • The development of VADs in China requires addressing significant challenges to meet clinical needs.
  • Further research and strategic planning are essential to accelerate the clinical translation of mechanical circulatory support.
  • Overcoming existing barriers is critical for advancing heart failure treatment options in China.

Keywords:
Axial pumpCentrifugal pumpIntra-aorta pumpVentricular assist devices

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.1K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

2.8K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790